Integrin receptor antagonists, in the form of RGD-antagonists or antibodies, have been shown to decrease angiogenesis, tumor growth and metastasis in several solid tumor types in which ITGAV is upregulated, including breast cancer, melanoma and prostate cancer. Here, ITGAV is linked to prostate cancer.